AAPL348.91+5.08 (+1.48%) ▲|ABBV290.79+4.80 (+1.68%) ▲|ABT104.57+1.93 (+1.88%) ▲|ACN247.22+3.82 (+1.57%) ▲|ADBE248.12-1.64 (-0.66%) ▼|AMAT421.66+5.66 (+1.36%) ▲|AMD566.42-12.02 (-2.08%) ▼|AMGN460.73+8.90 (+1.97%) ▲|AMT185.88+2.13 (+1.16%) ▲|AMZN243.79-10.81 (-4.25%) ▼|AVGO345.00-6.81 (-1.94%) ▼|AXP323.71+5.77 (+1.81%) ▲|BA172.65+5.51 (+3.30%) ▲|BAC51.14+0.29 (+0.57%) ▲|BKNG150.43+2.49 (+1.68%) ▲|BLK1,176.24+18.36 (+1.59%) ▲|BMY61.39+0.82 (+1.35%) ▲|BNY149.37+0.78 (+0.52%) ▲|BRK-B541.96+1.62 (+0.30%) ▲|C125.76+1.65 (+1.33%) ▲|CAT647.39-65.99 (-9.25%) ▼|CL93.16+1.47 (+1.60%) ▲|CMCSA22.27+0.70 (+3.25%) ▲|COF208.74+3.86 (+1.88%) ▲|COP150.03+0.97 (+0.65%) ▲|COST996.08+13.35 (+1.36%) ▲|CRM230.90-11.21 (-4.63%) ▼|CSCO108.59-1.70 (-1.54%) ▼|CVS90.33+0.38 (+0.42%) ▲|CVX231.46+2.26 (+0.99%) ▲|DE660.00+19.33 (+3.02%) ▲|DHR236.98+2.91 (+1.24%) ▲|DIS110.91+1.87 (+1.72%) ▲|DUK125.90+2.33 (+1.89%) ▲|EMR170.74+3.03 (+1.81%) ▲|FDX307.82+3.24 (+1.06%) ▲|GD370.82+16.47 (+4.65%) ▲|GE313.05+11.92 (+3.96%) ▲|GEV887.85+9.82 (+1.12%) ▲|GILD165.61+6.41 (+4.03%) ▲|GM85.72+3.24 (+3.93%) ▲|GOOG282.32-39.57 (-12.29%) ▼|GOOGL283.82-41.07 (-12.64%) ▼|GS927.73+2.56 (+0.28%) ▲|HD328.98+11.42 (+3.60%) ▲|HON222.14+2.88 (+1.31%) ▲|IBM258.28+5.06 (+2.00%) ▲|INTC92.07-3.46 (-3.62%) ▼|INTU331.19+3.00 (+0.91%) ▲|ISRG448.76+4.58 (+1.03%) ▲|JNJ275.20+4.16 (+1.53%) ▲|JPM343.58+4.28 (+1.26%) ▲|KO92.82+1.09 (+1.19%) ▲|LIN503.15-5.01 (-0.99%) ▼|LLY1,373.70+85.40 (+6.63%) ▲|LMT643.59+13.84 (+2.20%) ▲|LOW207.28+8.88 (+4.48%) ▲|LRCX254.39+0.57 (+0.22%) ▲|MA635.70+25.39 (+4.16%) ▲|MCD257.38+6.88 (+2.75%) ▲|MDLZ62.53+0.66 (+1.07%) ▲|MDT97.11+2.33 (+2.46%) ▲|META624.52+12.03 (+1.96%) ▲|MMM177.36+4.56 (+2.64%) ▲|MO76.75+3.76 (+5.15%) ▲|MRK146.33+5.40 (+3.83%) ▲|MS190.00-0.13 (-0.07%) ▼|MSFT530.14-0.87 (-0.16%) ▼|MU934.27-48.96 (-4.98%) ▼|NEE82.14+1.12 (+1.38%) ▲|NFLX62.05+0.06 (+0.10%) ▲|NKE38.42+1.27 (+3.42%) ▲|NOW109.67-40.46 (-26.95%) ▼|NVDA213.66-1.72 (-0.80%) ▼|ORCL139.56-4.98 (-3.45%) ▼|PEP133.79+1.16 (+0.87%) ▲|PFE29.95+0.50 (+1.70%) ▲|PG160.59+2.33 (+1.47%) ▲|PLTR196.42-0.39 (-0.20%) ▼|PM208.50+5.86 (+2.89%) ▲|QCOM185.41+2.44 (+1.33%) ▲|RTX199.40+3.56 (+1.82%) ▲|SBUX105.51+2.31 (+2.24%) ▲|SCHW89.47+0.71 (+0.80%) ▲|SO92.99+1.47 (+1.61%) ▲|SPG215.72+4.48 (+2.12%) ▲|T20.92+0.22 (+1.06%) ▲|TMO709.18+5.03 (+0.71%) ▲|TMUS147.29-0.79 (-0.53%) ▼|TSLA403.30-0.92 (-0.23%) ▼|TXN312.94+3.11 (+1.00%) ▲|UBER65.74+0.47 (+0.72%) ▲|UNH410.91+3.81 (+0.94%) ▲|UNP301.93+4.13 (+1.39%) ▲|UPS107.33+1.71 (+1.62%) ▲|USB60.64+1.04 (+1.75%) ▲|V410.54+9.94 (+2.48%) ▲|VZ43.66+0.48 (+1.11%) ▲|WFC84.81+1.14 (+1.36%) ▲|WMT121.25+2.48 (+2.09%) ▲|XOM183.29+1.27 (+0.70%) ▲|AAPL348.91+5.08 (+1.48%) ▲|ABBV290.79+4.80 (+1.68%) ▲|ABT104.57+1.93 (+1.88%) ▲|ACN247.22+3.82 (+1.57%) ▲|ADBE248.12-1.64 (-0.66%) ▼|AMAT421.66+5.66 (+1.36%) ▲|AMD566.42-12.02 (-2.08%) ▼|AMGN460.73+8.90 (+1.97%) ▲|AMT185.88+2.13 (+1.16%) ▲|AMZN243.79-10.81 (-4.25%) ▼|AVGO345.00-6.81 (-1.94%) ▼|AXP323.71+5.77 (+1.81%) ▲|BA172.65+5.51 (+3.30%) ▲|BAC51.14+0.29 (+0.57%) ▲|BKNG150.43+2.49 (+1.68%) ▲|BLK1,176.24+18.36 (+1.59%) ▲|BMY61.39+0.82 (+1.35%) ▲|BNY149.37+0.78 (+0.52%) ▲|BRK-B541.96+1.62 (+0.30%) ▲|C125.76+1.65 (+1.33%) ▲|CAT647.39-65.99 (-9.25%) ▼|CL93.16+1.47 (+1.60%) ▲|CMCSA22.27+0.70 (+3.25%) ▲|COF208.74+3.86 (+1.88%) ▲|COP150.03+0.97 (+0.65%) ▲|COST996.08+13.35 (+1.36%) ▲|CRM230.90-11.21 (-4.63%) ▼|CSCO108.59-1.70 (-1.54%) ▼|CVS90.33+0.38 (+0.42%) ▲|CVX231.46+2.26 (+0.99%) ▲|DE660.00+19.33 (+3.02%) ▲|DHR236.98+2.91 (+1.24%) ▲|DIS110.91+1.87 (+1.72%) ▲|DUK125.90+2.33 (+1.89%) ▲|EMR170.74+3.03 (+1.81%) ▲|FDX307.82+3.24 (+1.06%) ▲|GD370.82+16.47 (+4.65%) ▲|GE313.05+11.92 (+3.96%) ▲|GEV887.85+9.82 (+1.12%) ▲|GILD165.61+6.41 (+4.03%) ▲|GM85.72+3.24 (+3.93%) ▲|GOOG282.32-39.57 (-12.29%) ▼|GOOGL283.82-41.07 (-12.64%) ▼|GS927.73+2.56 (+0.28%) ▲|HD328.98+11.42 (+3.60%) ▲|HON222.14+2.88 (+1.31%) ▲|IBM258.28+5.06 (+2.00%) ▲|INTC92.07-3.46 (-3.62%) ▼|INTU331.19+3.00 (+0.91%) ▲|ISRG448.76+4.58 (+1.03%) ▲|JNJ275.20+4.16 (+1.53%) ▲|JPM343.58+4.28 (+1.26%) ▲|KO92.82+1.09 (+1.19%) ▲|LIN503.15-5.01 (-0.99%) ▼|LLY1,373.70+85.40 (+6.63%) ▲|LMT643.59+13.84 (+2.20%) ▲|LOW207.28+8.88 (+4.48%) ▲|LRCX254.39+0.57 (+0.22%) ▲|MA635.70+25.39 (+4.16%) ▲|MCD257.38+6.88 (+2.75%) ▲|MDLZ62.53+0.66 (+1.07%) ▲|MDT97.11+2.33 (+2.46%) ▲|META624.52+12.03 (+1.96%) ▲|MMM177.36+4.56 (+2.64%) ▲|MO76.75+3.76 (+5.15%) ▲|MRK146.33+5.40 (+3.83%) ▲|MS190.00-0.13 (-0.07%) ▼|MSFT530.14-0.87 (-0.16%) ▼|MU934.27-48.96 (-4.98%) ▼|NEE82.14+1.12 (+1.38%) ▲|NFLX62.05+0.06 (+0.10%) ▲|NKE38.42+1.27 (+3.42%) ▲|NOW109.67-40.46 (-26.95%) ▼|NVDA213.66-1.72 (-0.80%) ▼|ORCL139.56-4.98 (-3.45%) ▼|PEP133.79+1.16 (+0.87%) ▲|PFE29.95+0.50 (+1.70%) ▲|PG160.59+2.33 (+1.47%) ▲|PLTR196.42-0.39 (-0.20%) ▼|PM208.50+5.86 (+2.89%) ▲|QCOM185.41+2.44 (+1.33%) ▲|RTX199.40+3.56 (+1.82%) ▲|SBUX105.51+2.31 (+2.24%) ▲|SCHW89.47+0.71 (+0.80%) ▲|SO92.99+1.47 (+1.61%) ▲|SPG215.72+4.48 (+2.12%) ▲|T20.92+0.22 (+1.06%) ▲|TMO709.18+5.03 (+0.71%) ▲|TMUS147.29-0.79 (-0.53%) ▼|TSLA403.30-0.92 (-0.23%) ▼|TXN312.94+3.11 (+1.00%) ▲|UBER65.74+0.47 (+0.72%) ▲|UNH410.91+3.81 (+0.94%) ▲|UNP301.93+4.13 (+1.39%) ▲|UPS107.33+1.71 (+1.62%) ▲|USB60.64+1.04 (+1.75%) ▲|V410.54+9.94 (+2.48%) ▲|VZ43.66+0.48 (+1.11%) ▲|WFC84.81+1.14 (+1.36%) ▲|WMT121.25+2.48 (+2.09%) ▲|XOM183.29+1.27 (+0.70%) ▲|
15.3 C
New York
Friday, October 30, 2026

Tag: investigation

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. – NPCE

NEW YORK, June 22, 2025 /PRNewswire/ -- APomerantz LLP is investigating claims on behalf of investors of  NeuroPace, Inc. ("NeuroPace" or the "Company") (NASDAQ:...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rocket Pharmaceuticals, Inc. – RCKT

NEW YORK, June 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company")...

Lilly’s oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The...

The investigational once-daily pill lowered A1C by an average of 1.3% to 1.6% across doses, with improvements seen as early as four weeks, in adults...

Novo Nordisk advances early-stage obesity medication, amycretin, to phase 3 clinical development based on early-phase clinical trial results in people with obesity or excess...

Both subcutaneous and oral formulations will advance straight to phase 3 development based on completed clinical studies and feedback received from regulatory authorities1,2PLAINSBORO, N.J.,...

DATA BREACH ALERT: Edelson Lechtzin LLP Is Investigating Claims On Behalf Of Aflac Incorporated Customers Whose Data May Have Been Compromised

Edelson Lechtzin LLP is investigating data privacy claims regarding an incident at Aflac Incorporated

DATA BREACH ALERT: Edelson Lechtzin LLP Is Investigating Claims On Behalf Of Krispy Kreme Doughnut Corporation Customers Whose Data May Have Been Compromised

Edelson Lechtzin LLP is investigating claims regarding data privacy violations involving Krispy Kreme Doughnut Corporation

Lynch Carpenter Investigates Claims in Philadelphia Insurance Companies Data Breach

PITTSBURGH, June 20, 2025 (GLOBE NEWSWIRE) -- Philadelphia Insurance Companies (“PHYL”) recently announced a cybersecurity incident that resulted in the disruption of PHYL’s network operations across its systems. PHYL’s investigation into the incident is ongoing, and further details have not been made publicly available by PHYL.1

Decision Notice – CIRO Hearing Panel finds Ken Kin Kit Lui and Devina Master liable and imposes sanctions

TORONTO, June 20, 2025 /CNW/ - Following a disciplinary hearing held on June 11, 2025, a hearing panel of the Canadian Investment Regulatory Organization (CIRO)...

$2.15 Million in Sculptures by Sir Daniel Winn Stolen in Anaheim

Renowned Artist and John Wayne Airport Art Commissioner Targeted in Sophisticated Heist ANAHEIM, Calif., June 20, 2025 /PRNewswire/ -- Two monumental sculptures by internationally recognized...

SRPT INQUIRY: Sarepta Therapeutics, Inc. Investors that Lost Money may have been Affected by Fraud — Contact BFA Law (NASDAQ:SRPT)

Sarepta Therapeutics, Inc. investors that lost money are notified to contact BFA Law about its ongoing securities fraud investigation.

Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)

Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP

Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

Delta-like Ligand 3 Targeted Therapies Market is Predicted to Heat Up During the Forecast Period (2025-2034) Across 7MM Owing to a Robust Pipeline |...

The delta-like ligand 3 targeted therapies market is witnessing significant growth, driven by the rising incidence of small cell lung cancer (SCLC) and neuroendocrine...

CD5 Targeted Therapies CD5 Targeting CAR T Cell Therapy Clinical Trials Market Insight 2025

First CD5 Targeted Therapy Commercial Launch Expected By 2030 Says Kuick Research
First CD5 Targeted Therapy Commercial Launch Expected By 2030 Says Kuick Research 

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsInvestigation